Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Total Liabilities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Total Liabilities for 11 consecutive years, with $3.8 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 47.85% to $3.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 billion through Dec 2025, up 47.85% year-over-year, with the annual reading at $3.8 billion for FY2025, 47.85% up from the prior year.
  • Total Liabilities for Q4 2025 was $3.8 billion at BeOne Medicines, up from $3.5 billion in the prior quarter.
  • The five-year high for Total Liabilities was $3.8 billion in Q4 2025, with the low at $1.1 billion in Q4 2022.
  • Average Total Liabilities over 5 years is $2.3 billion, with a median of $2.2 billion recorded in 2022.
  • The sharpest move saw Total Liabilities crashed 54.31% in 2022, then soared 106.59% in 2023.
  • Over 5 years, Total Liabilities stood at $2.4 billion in 2021, then plummeted by 54.31% to $1.1 billion in 2022, then surged by 106.59% to $2.3 billion in 2023, then grew by 14.14% to $2.6 billion in 2024, then skyrocketed by 47.85% to $3.8 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.8 billion, $3.5 billion, and $2.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.